Table 2.
Age at time of diagnosis | Multiple-classifier EC | POLE variant | Tumor type | FIGO stage | Lymphovascular invasion | Clinical risk assessment | |
---|---|---|---|---|---|---|---|
Patient 1 | 76 | POLEmut and p53abn | P286R | endometrioid | IIIC2 | Yes | High |
Patient 2 | 75 | POLEmut and p53abn | P286R | carcinosarcoma | IB | Yes | High |
Patient 3 | 70 | MMRd and p53abn | wild-type | endometrioid | IA | No | Low |
Patient 4 | 87 | MMRd and p53abn | wild-type | endometrioid | IIIB | Yes | High |
Patient 5 | 53 | POLEmut and p53abn | P286R | endometrioid | IA | No | Low |
Patient 6 | 52 | POLEmut and p53abn | P286R | endometrioid | IA | No | Intermediate |
MMRd = mismatch repair deficient tumour; p53abn = p53 expression abnormal tumour; POLE = DNA polymerase-epsilon; POLEmut = POLE ultramutated tumour